New shot shows promise against tough lymphoma in japanese study
NCT ID NCT04542824
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy. The goal is to see if this immune-boosting shot can help control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab (also called EPKINLY™) is a drug given as a shot under the skin. It helps the immune system attack cancer cells.
What this could lead to
If this trial works, it could offer a new treatment option for Japanese patients with B-cell lymphoma that has come back or not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of patients, so results may not apply to everyone. Side effects are possible, and the drug may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Aichi, Japan
-
Cancer Institute Hospital of JFCR
Tokyo, Japan
-
Fukushima Medical University Hospital
Fukushima, Japan
-
Kagoshima University Hospital
Kagoshima, Japan
-
Kindai University Hospital
Osaka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Matsuyama Red Cross Hospital
Ehime, Japan
-
NHO Nagoya Medical Center
Aichi, Japan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
-
Osaka University Hospital
Osaka, Japan
-
Tohoku University Hoaspital
Sendai, Miyagi, 980-8577, Japan
-
Tokyo Medical University Hospital
Tokyo, Japan
-
Yamagata University Hospital
Yamagata, Japan